<DOC>
	<DOCNO>NCT00662740</DOCNO>
	<brief_summary>The primary objective study assess bronchodilator efficacy determine FEV1 , effect dyspnoea determine BDI/TDI , effect health status determine SGRQ effect COPD exacerbation .</brief_summary>
	<brief_title>Tiotropium/Salmeterol Inhalation Powder ( Spiriva Handihaler Salmeterol PE Capsule ) COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : Main : Diagnosis COPD Postbronchodilator FEV1 &lt; 80 % predict FEV1/FVC &lt; 70 % predict Exclusion criterion : Main : Significant disease COPD Recent MI Unstable lifethreatening arrythmia require intervention change drug therapy Hospitalisation cardiac failure past year History asthma</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>